Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program
The FDA granted accelerated approval to Boehringer Ingelheim’s oral HER2 kinase inhibitor Hernexeos six weeks after the company filed its application, marking the second approval under the new Commissioner’s National Priority Voucher (CNPV) program. The decision expands Hernexeos use to treatment‑naïve patients with unresectable or metastatic non‑small cell lung cancer, based on Phase 1b Beamion LUNG‑1 data showing a 76% overall response rate and durable responses in 64% of patients. The CNPV voucher accelerated the review from the typical 10‑12 months to roughly one to two months, but the program faces scrutiny after a recent high‑profile rejection of another voucher‑backed drug. Boehringer will need to complete a confirmatory trial to retain the accelerated approval.
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral
Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, posted $110 million in fourth‑quarter sales, bringing full‑year revenue to $898.7 million—well below the $1 billion benchmark. Safety incidents in 2025 and a severe flu season have eroded confidence, prompting analysts to project 2026...
FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution
The FDA announced it will default to a single pivotal trial for new drug applications, extending a practice long used in oncology and rare‑disease approvals. In 2024, 66% of new molecular entities were cleared based on one trial, signaling a...
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
The latest episode of BioSpace’s Denatured podcast spotlights a growing partnership between ALS patients and pharmaceutical developers, featuring insights from EverythingALS founder Indu Navar and VectorY Therapeutics CMO Dr. Olga Uspenskaya. The discussion highlights how patient‑driven collaborations are accelerating trial timelines...
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
Atara Biotherapeutics’ stock jumped 20% after STAT reported that internal FDA inconsistencies may have driven the rejection of its EBV‑positive PTLD cell therapy, Ebvallo. The FDA denied the U.S. application citing insufficient evidence of effectiveness, yet former reviewers said data...
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
Pfizer has signed a global gene‑editing partnership with Beam Therapeutics, reviving its genetics ambitions after withdrawing the hemophilia B therapy Beqvez a year earlier. The agreement includes a $300 million upfront payment and up to $1.05 billion in milestones, granting Pfizer exclusive worldwide...
The Right Fit: Contract Work Finds Increasing Favor Among Employers, Professionals
BioSpace data shows contract biopharma job postings jumped 36.7% from Jan 2025 to Jan 2026 while full‑time listings fell 11.3%. A 2026 employment outlook survey found contract workers now represent 14.3% of respondents, up from 10.6% in 2023. Recruiters say the shift...
10 Companies Hiring in San Francisco and South San Francisco
San Francisco and South San Francisco remain biotech hubs, employing over 113,700 workers according to a Cushman & Wakefield report. Although BioSpace job postings fell sharply in January, listings are now climbing, with ten companies actively hiring. Companies such as AbbVie, Amgen, Eli Lilly and Ideaya...
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
A patient in MacroGenics' Phase 2 LINNET trial of the bispecific antibody lorigerlimab suffered grade 4 neutropenia and septic shock, leading to a fatality and prompting the FDA to place a partial clinical hold on the study. The company also reported three...
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Eli Lilly’s obesity drug Zepbound achieved a 25.5% weight loss in a head‑to‑head Phase 3 trial, outpacing Novo Nordisk’s CagriSema and sending Novo’s shares down 20%. The FDA launched Rare Disease Week, issuing draft guidance for a new Plausible Mechanism Pathway that...
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
In July 2025 the FDA ordered a complete halt of Sarepta’s gene‑therapy Elevidys after two non‑ambulatory Duchenne muscular dystrophy (DMD) patients died, sparking a market plunge and patient access concerns. Sarepta argues that ambulatory patients, who had been receiving Elevidys...
How LB Rode the Brutal Capital Markets to One of 2025’s Most Successful IPOs
LB Pharma went public in September 2024, pricing its shares at $15 and raising $285 million despite a severely constrained capital market. The IPO followed a Phase 2 trial that showed LB‑102 markedly reduced schizophrenia symptoms, sparking investor demand even as venture...
Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D
The FDA reauthorized its rare pediatric disease priority review voucher program, bolstering a wave of regulatory incentives that include new guidance on plausible mechanisms and a Rare Disease Evidence Principles framework. Yet ultra‑rare indications still struggle to attract traditional venture...
Cut Down on Oncology Drug Waste With Better Forecasting
Oncology drug waste reaches up to 30%, costing over $2 billion annually in the U.S. A 2023 CMS rule now forces manufacturers to refund Medicare for discarded volumes beyond a 10% threshold, adding financial pressure. Traditional forecasting relies on static sales...
Radiopharmaceutical Sector Shapes Supply Chain Around Fast-Decaying Products
Radiopharmaceutical manufacturers must design ultra‑fast supply chains because isotopes decay rapidly, turning each dose into a ticking clock. Companies such as NorthStar and Nucleus mitigate this by locating production near major airports, using private air freight for longer‑half‑life isotopes, and...
Merck Reorganizes Human Health Work Into Two New Units
Merck is reorganizing its Human Health division into two distinct units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen focus as its flagship immuno‑oncology drug Keytruda approaches patent expiry. Jannie Oosthuizen, formerly head of U.S. Human Health, will lead the Oncology...
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
An appellate court reversed a lower‑court ruling, siding with REGENXBIO in its patent dispute against Sarepta Therapeutics over an adeno‑associated virus (AAV) vector used in Duchenne muscular dystrophy gene therapy. The judge held that the patented composition, as a whole,...
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
Novo Nordisk’s experimental obesity drug CagriSema delivered a 23% average weight loss in the 84‑week REDEFINE 4 Phase 3 trial, but fell short of Eli Lilly’s tirzepatide (Zepbound) which achieved 25.5%. The head‑to‑head study failed the primary non‑inferiority endpoint, prompting a 15% drop...
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
In February 2024 Vertex and CRISPR Therapeutics launched Casgevy, and bluebird bio (now Genetix Biotherapeutics) launched Lyfgenia as the first FDA‑approved gene therapies for sickle cell disease. Two years later, uptake remains modest—only 64 patients received Casgevy and just over 100...
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
Madrigal’s Rezdiffra became the first approved therapy for metabolic dysfunction‑associated steatohepatitis (MASH), generating $817 million in revenue within six quarters and prompting a wave of big‑pharma acquisitions focused on FGF21 analogs. In 2025, GSK, Roche and Novo Nordisk spent nearly $10 billion acquiring...
Redefining Obesity Treatment Beyond GLP-1 Limits
BioSpace’s Denatured podcast featured Verdiva Bio’s R&D head Jane Hughes and MitoRx CEO Jon Rees discussing next‑generation obesity therapies that move beyond the limitations of GLP‑1 agonists. They highlighted how GLP‑1 treatments can cause muscle loss and suffer from poor...
9 Companies Hiring Now in Pennsylvania
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
Extending Scientific Rigor From Bench to Boardroom
Researchers who launch biotech startups often abandon evidence‑based decision‑making once they enter the boardroom, falling prey to technology myopia, base‑rate neglect, and confirmation bias. Their lack of formal training in commercialization, financial modeling, and competitive analysis amplifies these pitfalls, leading...
Korsana Joins Alzheimer's Amyloid Arena With $150M Debut, Next-Gen Antibody
When Senior Leaders Are Asked To Carry Too Much
Biopharma senior leaders are increasingly shouldering operational work left behind by downsizing, stretching their capacity beyond strategic duties. The overload fragments focus, slows decisions, and erodes communication, while burnout remains hidden behind continued presence. As pressure builds, the organization’s decision‑making...
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
Venture capital in biopharma rebounded in 2025, delivering $33.8 billion across 1,171 deals, but the capital is increasingly concentrated in late‑stage companies. Early‑stage startups received only 32% of the funding, down from over 40% during the pandemic surge, while median deal...
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
Regulatory uncertainty is rising as the FDA shifts leadership, adopts a single‑trial approval pathway, and tightens its benefit‑risk framework. While the one‑trial standard promises faster, cheaper market entry, recent surprise complete response letters (CRLs) show that even successful Phase 3 results...
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Ionis Therapeutics announced that its GSK‑partnered antisense drug bepirovirsen achieved a statistically significant functional cure rate of roughly 15‑20% in a Phase 3 trial, far surpassing the 1‑3% rate of existing hepatitis B therapies. The company also reported a strong first‑year launch...
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
A new analysis in Health Affairs Scholar reveals that brand‑name drugmakers are exploiting the Hatch‑Waxman framework through serial patent litigation and continuation patents to extend market exclusivity. By filing multiple overlapping patents, companies can repeatedly sue generic challengers, triggering 30‑month...
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
Vaxart is advancing an oral, bivalent norovirus vaccine pill (VXA‑G1.1‑NN) that demonstrated a 30% reduction in infection in a Phase 2b challenge study. The vaccine uses a non‑replicating adenovirus vector loaded with a dsRNA adjuvant to stimulate gut immunity, and a...
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
The FDA is actively phasing out animal‑testing requirements for certain therapies, a move echoed by the NIH and codified in the pending FDA Modernization Act. This regulatory shift opens the door for artificial intelligence and human‑derived organoid models to become...
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
Biopharma faces a tightening fetal bovine serum (FBS) market as U.S. cattle inventories hit record lows and European disease outbreaks curb supply. Prices have surged more than 300% over five years and release timelines have lengthened from weeks to months...
2025 Q4 Job Market Report: Positive Signs Emerge for Job Seekers
The fourth quarter of 2025 marked the first quarter‑over‑quarter rise in biopharma job postings, with a 10% increase and a 4% uptick in average listings, despite a 14% year‑over‑year decline. Science/research and development roles grew 14% while clinical positions surged...
‘Just Agree to It:’ Pazdur Said He Was Told To Cosign FDA’s Reduced Trial Requirements
Richard Pazdur, longtime FDA oncology leader, resigned after being pressured to endorse a controversial policy that would reduce required drug approval trials from two to one. He said Commissioner Marty Makary breached the traditional independence between the commissioner’s office and...
2026 Could Mark a Turning Point for American Innovation
The United States faces a potential decline in biotech leadership as recent Supreme Court decisions blur patent eligibility and congressional price‑control measures under the Inflation Reduction Act force program cancellations. Proposals to seize university licensing revenue further strain tech‑transfer offices,...
How DIA Is Helping Regulators Turn AI Principles Into Everyday Review Practice
At the 2026 DIA Global Annual Meeting, the DIA AI Consortium will showcase how regulators such as the FDA are embedding artificial intelligence into medical product review workflows. The FDA’s 2025‑2026 roadmap uses AI to automate routine tasks, accelerate timelines,...
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp
Vertex Pharmaceuticals and CRISPR Therapeutics forecast combined Casgevy gene‑therapy and Journavx pain‑drug sales of $500 million in 2026, a 185 % jump from 2025. The therapy generated $115.8 million in 2025, with Q4 revenue of $54.8 million, and treated 111 patients that year, up...
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
Vertex Pharmaceuticals reported that its late‑stage RAINIER trial of povetacicept in IgA nephropathy is proceeding without safety concerns, with primary data expected in the first half of 2026. The company is leveraging a priority‑review voucher for the upcoming FDA filing...
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Evommune’s shares surged 75% after its Phase 2a trial showed the therapeutic protein EVO301 reduced atopic dermatitis severity by 33% versus placebo. The study enrolled 70 patients, with a 55% reduction in the treatment arm compared to 22% in the placebo...
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
The latest wave of antibody‑drug conjugates (ADCs) hinges on precise HER2 quantification, and digital pathology combined with AI is delivering that accuracy. By analyzing gigapixel slides, AI models can detect low and ultra‑low HER2 expression that traditional microscopy often misses,...
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
Investment in radiopharmaceuticals is driving a fierce talent shortage as big‑pharma players like AstraZeneca, Novartis and Eli Lilly expand into the modality. The success of lutetium‑177 therapies such as Lutathera and Pluvicto has sparked a surge in clinical studies, intensifying demand...
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Biogen expects Phase 2 readout for its tau‑targeting antisense oligonucleotide BIIB080 in the second or third quarter of 2026. The CELIA trial evaluates three dose levels through week 76 and uses cognition as the primary endpoint. A positive signal could lift Biogen’s...
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
UniQure paused dosing in the mid- and high-dose arms of its Phase 1/2a Fabry gene‑therapy trial after two patients experienced grade 3 liver enzyme elevations. The affected cohorts received 4 × 10¹³ and 6 × 10¹³ genome copies per kilogram of AMT‑191, while the low‑dose group...
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
Ultragenyx reported that its investigational AAV gene therapy UX111 delivers sustained cognitive improvements in Sanfilippo A patients, with follow‑up extending up to 8.5 years. Data from 33 dosed participants—27 receiving the highest dose—showed a 23.3‑point gain on the Bailey‑III scale...
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
2026 regulatory landscape sees the FDA reviving the rare‑pediatric disease priority review voucher (PRV) program, launching the PreCheck manufacturing pilot, and issuing new guidance for multiple myeloma trials and GLP‑1 label warnings. The PRV reinstatement restores a $150 million voucher market,...
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Bristol Myers Squibb posted fourth‑quarter 2025 sales of $12.5 billion, topping the $12.28 billion consensus. Eliquis generated $3.4 billion, falling short of expectations, while the new schizophrenia drug Cobenfy earned $51 million, missing forecasts by 3 %. Despite the miss, BMS forecasts 10‑15 % Eliquis growth...
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Novartis announced the removal of six Phase 1 oncology candidates—including KFA115, HRO761, MGY825, and AAA802—from its pipeline and introduced two new Phase 1 assets, AMO959 for prostate cancer and GCJ904 for solid tumors. The reshuffle aligns with a strategic review aimed at...
Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq
PrimeGen US is set to go public on Nasdaq in 2026 by merging with SPAC DT Cloud Star Acquisition Corp., valuing the stem‑cell biotech at roughly $1.5 billion. The $69 million‑raised SPAC will provide capital to advance PrimeGen’s triple‑activated mesenchymal stem cell...
Programmable RNA 2.0: Beyond the First mRNA Revolution
BioSpace’s Denatureed podcast episode "Programmable RNA 2.0" spotlights the next wave of RNA therapeutics beyond the COVID‑19 mRNA vaccine success. Host Jennifer Smith‑Parker interviews Erik Digman Wiklund of Circio and Jacob Becraft of Strand Therapeutics about emerging platforms such as circular RNA...
3 Top Challenges Facing Regulatory Professionals Right Now
Regulatory professionals are grappling with three pressing challenges: vague FDA and EMA AI guidance, the mismatch between rapidly evolving AI models and static regulatory frameworks, and a constrained supply chain for radiopharmaceuticals. Experts stress that AI‑driven submissions must rest on...